PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.

MLA

Tao, Hongru, et al. “PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.” Cancer Research, vol. 84, no. 3, Feb. 2024, pp. 419–33. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-23-1082.

APA

Tao, H., Jin, C., Zhou, L., Deng, Z., Li, X., Dang, W., Fan, S., Li, B., Ye, F., Lu, J., Kong, X., Liu, C., Luo, C., & Zhang, Y. (2024). PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma. Cancer Research, 84(3), 419–433. https://doi.org/10.1158/0008-5472.CAN-23-1082

Chicago

Tao, Hongru, Chen Jin, Liyuan Zhou, Zhenzhong Deng, Xiao Li, Wenzhen Dang, Shijie Fan, et al. 2024. “PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma.” Cancer Research 84 (3): 419–33. doi:10.1158/0008-5472.CAN-23-1082.